Hatice SÜRER, Seçil Pervane VURAL, Pınar BORMAN, Damla DEDEBAYRAKTAR, Pelin BİLGİÇ, Sümeyra ÖTELEŞ, Seher KOCAOĞLU

ROMATOİD ARTRİTLİ HASTALARDA SERUM ADİPONEKTİN VE VÜCUT KOMPOZİSYONU PARAMETRELERİNİN HASTALIK AKTİVİTESİ İLE İLİŞKİSİ

GİRİŞ: Romatoid artrit eklem dokusunun ilerleyici yıkımı nedeniyle eklemlerde şişme ve hassasiyetle sonuçlanan ilerleyici inflamatuar bir hastalıktır. Adiponektin, adipoz dokudan sentezlenir ve bazı izoformların pro-inflamatuar özellikleri gösterdiği ve adiponektinin romatoid artrit patofizyolojisinde önemli bir etkiye sahip olduğu bildirilmiştir. Çeşitli vücut kompozisyonu ölçümleri ve yaşam kalitesi skorlarının diğer hastalık parametreleri ile ilişkisini inceleyen çalışmaların eksik olduğuna inanıyoruz. Çalışmamızda romatoid artrit hastalarında bu parametrelerin ilişkisini incelemeyi hedefledik. MATERYAL-METHOD: Çalışmaya romatoid artrit tanısı ile merkezimize başvuran 54 hasta (11 erkek, 44 kadın) dahil edildi. Hastaların hastalık parametreleri, hastalık aktivite skorları, antropometrik ölçümleri, vücut kompozisyon parametreleri, serum adiponektin düzeyleri ve hastalık parametrelerinin yaşam kalitesi anket sonuçları kaydedildi. Metabolik sendrom varlığı da değerlendirildi ve kayıt edildi. SONUÇLAR: Adiponektin ile vücut yağı (%) ve yağlı vücut kitlesi arasında pozitif korelasyon ve yağsız vücut kitlesi (%) arasında ise negatif korelasyon vardı. Adiponektin düzeyleri ile diğer hastalık pa- rametreleri arasında anlamlı ilişki bulunamadı. Ayrıca, RA-QoL ve yağsız kütle arasındaki anlamlı negatif korelasyon dışında, hastalık parametrelerinin hiçbiri antropometrik ölçümler ve vücut kompozis- yonu sonuçları ile belirgin bir ilişki göstermedi. Çalışmanın şaşırtıcı bir bulgusu metabolik sendromlu hastalarda hastalık süresinin an- lamlı olarak daha kısa olmasıydı. SONUÇ: Adiponektin izoform ölçümleri ve hastalık aktivitesi durumu arasındaki multifaktöriyel patogenez, adiponektin ve ilgili parametre- lerin değerlendirilmesinde dikkate alınmalıdır. Farklı hastalık aktivi- tesine sahip hastaları içeren gelecekteki çalışmalar çelişkili sonuçları açıklayabilir.

SERUM ADIPONECTIN AND BODY COMPOSITION PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS: RELATIONSHIP WITH DISEASE ACTIVITY

INTRODUCTION: Rheumatoid arthritis is a progressive inflammatorydisease which results in swelling and tenderness in joints due toprogressive destruction of joint tissue. Adiponectin is synthesized by theadipose tissue and at least some isoforms have been shown to displaypro-inflammatory properties and also adiponectin was reported to havean important affect in rheumatoid arthritis pathophysiology. We believethat studies are lacking in terms of comparing a broad range of bodycomposition measurements and quality of life scores with other diseaseparameters. In our study we aim to investigate the relationship betweenthese parameters in rheumatoid arthritis patients.MATERIALS AND METHODS: Fifty-five patients (11 males, 44female) who applied to our center with an rheumatoid artritis diagnosiswere included to the study. Patients’ disease parameters, disease activityscores, anthropometric measurements, body composition parameters,serum adiponectin levels and disease parameters quality of life surveyresults were recorded. The presence of metabolic syndrome was alsoassessed and saved.RESULTS: Adiponectin was positively correlated with body fat (%)and fat mass index (FMI), and negatively correlated with fat-free mass(%). No significant correlations were found between adiponectinlevels and other disease parameters. Furthermore, none of the diseaseparameters showed any remarkable association with anthropometricmeasurements and body composition results, apart from a significantnegative correlation between RA-QoL and fat-free mass. A surprisingfinding of the study was the fact that disease duration was significantlyshorter in patients with metabolic syndrome.CONCLUSION: Multifactorial pathogenesis between adiponectinisoform measurements and disease activity status should be consideredin the evaluation of adiponectin and related parameters Future studiescomprising patients with different disease activity may explain conflictingresults.

PDF

___

1.)Boissier M-C, Semerano L, Challal S, Saidenberg-Kermanac'h N, Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun. 2012;39(3):222-228.
2.)Longo D, Fauci A, Kasper D. (2011) Harrison’s Principles of Internal Medicine (18th edn).
3.)Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet.2010;376(9746):1094-108.
4.)Ikeoka D, Mader JK, Pieber TR. Adipose tissue, inflammation and cardiovascular disease. Rev Assoc Med Bras. 2010;56(1):116-121.
5.)Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. BMJ (Clinical research ed.) 1984;288(6428):1401-1404.
6.)Kaul S, Rothney MP, Peters DM, Wacker WK, Davis CE, Shapiro MD, et al. Dual-energy X-ray absorptiometry for quantification of visceral fat. Obesity (Silver Spring). 2012;20(6):1313-8.
7.)Despres JP. Body fat distribution and risk of cardiovascular disease: an update. Circulation. 2012;126(10):1301-13.
8.)Rajala MW, Scherer PE. Minireview: The adipocyte--at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144(9):3765-73.
9.)Frommer KW, Zimmermann B, Meier FM, Schröder D, Heil M, Schäffler A, et al. Adiponectin‐mediated changes in effector cells involved in the pathophysiology of rheumatoid arthritis. Arthritis Rheum. 2010;62(10):2886-2899.
10.)Behre CJ. Adiponectin, obesity and atherosclerosis. Scand J Clin Lab Invest.2007;67(5):449-58.
11.)Pyrzak B, Ruminska M, Popko K, Demkow U. Adiponectin as a biomarker of the metabolic syndrome in children and adolescents. Eur J Med Res. 2010;15(2):147.
12.)Chen X, Lu J, Bao J, Guo J, Shi J, Wang Y. Adiponectin: a biomarker for rheumatoid arthritis? Cytokine Growth Factor Rev. 2013;24(1):83-9.
13.)Tang CH, Chiu YC, Tan TW, Yang RS, Fu WM. Adiponectin enhances IL-6 production in human synovial fibroblast via an AdipoR1 receptor, AMPK, p38, and NF-kappa B pathway. J Immunol. 2007;179(8):5483-92.
14.)Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum.1995;38(1):44-8.
15.)T Uhlig, E. A. Haavardsholm, T. K. Kvien. Comparison of the Health Assessment Questionnaire (HAQ) and the modified HAQ(MHAQ)in patient with rheumatoid artritis.Rheumatology. 2005; 45(4): 454-458.
16.)G. J. Tijhuis, Z. de Jong, A. H. Zwinderman, W. M. Zuijderduin,L. M. A. Jansen, J. M. W. Hazes, et al.The validity of the Rheumatoid arthritis Quality of Life (RAQoL) questionnaire. Rheumatology. 2001 ;40 (10): 1112-1119.
17.)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421.
18.)WHO EC. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England) 2004;363(9403):157.
19.)Armstrong D, McCausland E, Quinn A, Wright G. Obesity and cardiovascular risk factors in rheumatoid arthritis. Rheumatology 2006;45(6):782-782.
20.)Crowson CS, Matteson EL, Davis JM, Gabriel SE. Contribution of obesity to the rise in incidence of rheumatoid arthritis. Arthritis Care Res. 2013;65(1):71-77.
21.)Younis KR, Al-Bustany DA. Prevalence of obesity in rheumatoid arthritis and its association with disease activity and latex positivity in a sample of patients in Erbil. Zanco J. Med. Sci. 2017; 21(2).
22.)Mattsson S, Thomas BJ. Development of methods for body composition studies. Phys Med Biol. 2006;51(13):R203.
23.)Sahin G, Guler H, Incel N, Sezgin M. Soft tissue composition, axial bone mineral density, and grip strength in postmenopausal Turkish women with early rheumatoid arthritis: Is lean body mass a predictor of bone mineral density in rheumatoid arthritis? Int J Fertil Womens Med. 2006;51(2):70-74.
24.)Book C, Karlsson MK, Åkesson K, Jacobsson LT. Early rheumatoid arthritis and body composition. Rheumatology 2009;48(9):1128-1132.
25.)Ajeganova S, Andersson ML, Hafström I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: A long‐term followup from disease onset. Arthritis care & research 2013;65(1):78-87.
26.)Jurgens MS, Jacobs JW, Geenen R, Bossema ER, Bakker MF, Bijlsma JW, et al. Increase of body mass index in a tight controlled methotrexate‐based strategy with prednisone in early rheumatoid arthritis: Side effect of the prednisone or better control of disease activity? Arthritis Care Res. 2013;65(1):88-93.
27.)Ferraccioli G, Gremese E. Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Med Wkly .2011;141:w13211.
28.)Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772-783.
29.)Kamel SR, Sadek HA, Mohamed FA, Ali LH, Osman HM. Differences in body mass index, waist circumference, and waistto-hip ratio in patients with rheumatoid arthritis: association with serum adiponectin and disease parameters. Egypt Rheum Rehabil. 2017;44(1):24.
30.)Baker JF, George M, Baker DG, Toedter G, Von Feldt JM, Leonard MB. Associations between body mass, radiographic joint damage, adipokines and risk factors for bone loss in rheumatoid arthritis. Rheumatology 2011;50(11):2100-2107.
31.)Oranskiy SP, Yeliseyeva LN, Tsanaeva AV, Zaytseva NV. Body composition and serum levels of adiponectin, vascular endothelial growth factor, and interleukin-6 in patients with rheumatoid arthritis. Croat Med J. 2012;53(4):350-356.
32.)Šenolt L, Pavelka K, Housa D, Haluzik M. Increased adiponectin is negatively linked to the local inflammatory process in patients with rheumatoid arthritis. Cytokine 2006;35(5):247-252.
33.)Lee YH, Bae SC. Circulating adiponectin and visfatin levels in rheumatoid arthritis and their correlation with disease activity: A meta‐analysis. Int J Rheum Dis. 2018 Mar; 21(3):664-672.
34.)Toussirot É, Grandclément É, Gaugler B, Michel F, Wendling D, Saas P, et al. Serum adipokines and adipose tissue distribution in rheumatoid arthritis and ankylosing spondylitis. A comparative study. Front Immunol. 2013;4:453.